Investigating the Risk of Adverse Cardiovascular Events Associated with Concomitant Treatment of Clopidogrel and Protein Pump Inhibitors

Investigating the Risk of Adverse Cardiovascular Events Associated with Concomitant Treatment of Clopidogrel and Protein Pump Inhibitors

Proton pump inhibitors (PPIs) are commonly coadministered with clopidogrel, an antiplatelet agent, to patients with acute coronary syndrome (ACS). Mechanistic studies suggest that PPIs have the potential to competitively inhibit the bioactivation of clopidogrel and may attenuate its antiplatelet act...

Full description

Bibliographic Details
Main Author: Farhat, Nawal
Other Authors: Krewski, Daniel Richard
Format: Others
Language:en
Published: Université d'Ottawa / University of Ottawa 2019
Subjects:
Electronic health records
Cardiovascular
Drug-drug interactions
Proton pump inhibitor
Drug safety
Epidemiology
Systematic review
Meta-analysis
Acute coronary syndrome
Real-world data
Online Access:http://hdl.handle.net/10393/38874
http://dx.doi.org/10.20381/ruor-23126

Internet

http://hdl.handle.net/10393/38874
http://dx.doi.org/10.20381/ruor-23126

Similar Items